Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan-Feb;179(1-2):35-48.
doi: 10.1016/j.neurol.2022.11.006. Epub 2022 Dec 30.

Treatment of Charcot-Marie-Tooth neuropathies

S Beloribi-Djefaflia  1 , S Attarian  2
Affiliations
Review

Treatment of Charcot-Marie-Tooth neuropathies

S Beloribi-Djefaflia et al. Rev Neurol (Paris). 2023 Jan-Feb.

Abstract

Charcot-Marie-Tooth (CMT) is a heterogeneous group of inherited neuropathies that affect the peripheral nerves and slowly cause progressive disability. Currently, there is no effective therapy. Patients' management is based on rehabilitation and occupational therapy, fatigue, and pain treatment with regular follow-up according to the severity of the disease. In the last three decades, much progress has been made to identify mutations involved in the different types of CMT, decipher the pathophysiology of the disease, and identify key genes and pathways that could be targeted to propose new therapeutic strategies. Genetic therapy is one of the fields of interest to silence genes such as PMP22 in CMT1A or to express GJB1 in CMT1X. Among the most promising molecules, inhibitors of the NRG-1 axis and modulators of UPR or the HDACs enzyme family could be used in different types of CMT.

Keywords: Charcot Marie Tooth; Gene therapy; Inherited neuropathy; Management; Therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

LinkOut - more resources